inVentiv Health plans to open a new Phase I/IIA clinic in Miami, expanding its Phase I clinical services into the U.S. The new clinic is expected to begin studies in 2H15. The new site compliments inVentiv’s clinical facility in Quebec, Canada.
 
The 65-bed Miami clinic, located in the University of Miami Life Science and Technology Park, will focus on studies including first-in-human Phase I, Phase I-in-patient and other Phase I trials such as drug-drug interaction, biosimilar, first-to-file and 505b2 trials.
 
“Phase I clinical research continues to become more complex, requiring rapid recruitment of unique  patient and special populations,” said Riaz Bandali, president  of  the  Early  Stage business unit for inVentiv Health’s Clinical Division. “The location of the clinic in the U.S., specifically in Miami, will help provide broad patient access thanks to a large population and diverse demographic. This should enable us to better meet the needs of our clients as they navigate the complex regulatory environment of drug development and approval.”